Loading...
•
Mar 31, 2021
Vaxcyte Q1 2021 Earnings Report
Vaxcyte reported financial results for the first quarter of 2021 and provided a business update.
Key Takeaways
Vaxcyte is advancing its VAX-24 program towards IND submission and has made progress on its pipeline vaccines, VAX-XP and VAX-A1. The company's cash, cash equivalents, and investments totaled $370.9 million as of March 31, 2021.
Advanced VAX-24 IND-enabling activities, making progress toward completion of GMP conjugated drug substances.
Published new research supporting VAX-24 and Vaxcyte’s technology platform, demonstrating robust immune responses in preclinical studies.
Appointed Janet Graesser as Vice President of Corporate Communications and Investor Relations.
Reaffirmed guidance for pipeline programs, including VAX-24 IND submission expected between January and June 2022.
Vaxcyte
Vaxcyte
Forward Guidance
Vaxcyte reaffirmed its previously issued guidance for its pipeline programs.
Positive Outlook
- VAX-24: Vaxcyte expects to submit an IND application for VAX-24 to the FDA between January and June 2022.
- VAX-24: Vaxcyte expects to announce topline data from the ensuing Phase 1/2 clinical proof-of-concept study between late 2022 and early 2023.
- VAX-A1: Following the nomination of its final vaccine candidate for VAX-A1 in the first quarter of 2021, Vaxcyte plans to initiate IND-enabling studies in the second half of 2021.
- VAX-PG: Vaxcyte expects to nominate a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, in the second half of 2021.